Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Brain Neoplasm: early-phase trial registry

4 of 10 indexed Brain Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Brain Neoplasm: 10 US clinical trials tracked, 4 recruiting.

Brain Neoplasm is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition brain-neoplasm

OPEN 4 | RECR 40% | LATE 0 | EARLY 3 | RANK #1724 | SPON 4

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Brain Neoplasm (this)40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Brain Neoplasm

Brain Neoplasm lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Brain Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Brain Neoplasm is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Brain Neoplasm research.

    M.D. Anderson Cancer Center accounts for 4 of 10 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Brain Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 44 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. Brain Neoplasm splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Open and recent trials

10 total, page 1 of 1

RECRUITING 100 participants

Tumor Related Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT02639325

RECRUITING NA 75 participants

Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

M.D. Anderson Cancer Center

NCT02754544

RECRUITING Phase 2 37 participants

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Northwell Health

NCT02800486

RECRUITING Phase 1 33 participants

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Northwell Health

NCT02861898

ACTIVE NOT RECRUITING 100 participants

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

M.D. Anderson Cancer Center

NCT04553757

ACTIVE NOT RECRUITING NA 45 participants

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

Children's Oncology Group

NCT01503086

ACTIVE NOT RECRUITING NA 32 participants

Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors

M.D. Anderson Cancer Center

NCT03606161

ACTIVE NOT RECRUITING 9 participants

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

M.D. Anderson Cancer Center

NCT05087888

COMPLETED 44 participants

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

University of Rochester

NCT00178295

COMPLETED Phase 1 10 participants

Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

Monteris Medical

NCT00747253

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Brain Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
3 trials
Intra-arterial Mannitol Drug
2 trials
Intra-arterial Cetuximab Drug
2 trials
AutoLITT system Device
1 trials
Psychosocial Assessment and Care Procedure
1 trials
Computer-Assisted Cognitive Training Other
1 trials
Electrocorticography Other
1 trials
Direct Electrocortical Stimulation Procedure
1 trials

US sites by state

Facility locations filed on Brain Neoplasm trials. A trial with sites in several states counts in each.

Texas 4 trials
New York 4 trials
Tennessee 1 trials
South Carolina 1 trials
Pennsylvania 1 trials
Ohio 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Brain Neoplasm page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Neoplasm condition card totals 10 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.